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1. Introduction 
Characterized by low platelet counts, immune thrombocytopenic purpura (ITP) has been 
discovered to be an acquired autoimmune disorder since the mid-1900s (Evans et al., 1951).  
In the 21st century, the modern generation would shudder at Harrington and 
Hollingsworth’s experiment they performed to search for the pathogenesis of ITP.  By 
injecting themselves with 500 ml of blood from a patient from low platelet counts, they 
developed the same bleeding disorder and were able to reproduce the disease in themselves 
(Harrington et al., 1951). Since that experiment, the pathogenesis and the therapeutic 
options of ITP have evolved by leaps and bounds. The traditional model of ITP is that of 
pathologic destruction of platelets by antiplatelet antibody. For many decades, this model of 
autoimmune thrombocytopenic purpura has shaped our understanding of the disorder and 
our therapeutic management of ITP (Buchanan et al, 1977, Hou et al. 1995, Fujisawa K et al. 
1992). Recent studies have broadened our perspective beyond humoral dysregulation to 
include the cellular immune system and abnormalities of megakaryocytes as well (Olsson, et 
al., 2003, Ballem et al., 1987, McMillan et al., 2004). These recent findings have opened the 
door for new treatment possibilities for ITP.  
In contrast to a more predictable clinical course of acute ITP, the pathogenesis, natural 
history and management of chronic ITP are significantly more diverse and rapidly evolving. 
The established treatment practices for chronic ITP have also undergone a major change. 
After a long period of standard treatment approach using steroids, splenectomy, and 
immunosuppressive therapy, a breakthrough came with the use of B-cell depletion therapy 
(Cines and McMillan, 2005). The availability of monoclonal antibody, rituximab, has led 
hematologists to reconsider the role of splenectomy in the frontline management of chronic 
ITP (Arnold et al., 2007). A new era has begun with the development of thrombopoietin-
mimetic agents that stimulate megakaryocytes to grow and produce platelets (Nurden et al., 
2009). 
Since chronic ITP remains a heterogeneous disorder; there is no consensus on the definite 
diagnostic criteria and management. In 1996, the American Society of Hematology 
published a landmark paper recommending guidelines to assist clinicians in the 
management of ITP (George et al., 1996). Since then, there have been tremendous advances 
in the management of both adult and pediatric ITP. These guidelines were updated by the 
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American Society of Hematology in 2010 (Neunert et al., 2010). In addition, an International 
Working Group (IWG) of experts on ITP attempted to bring some uniformity to the 
diagnosis and management of ITP (Rodeghiero et al., 2009). Despite the serious efforts of 
scientists and specialty societies, the practicing hematologists are still left with many 
unanswered questions and dilemmas when it comes to treating this benign but challenging 
disease. 
Until recently, adult ITP was considered a disease of young women.  However, two recently 
published studies have shown otherwise (Schoonen et al. 2009, Abrahamson et al., 2009). In 
these series, the mean ages at presentation were over 50 years, with a slight female 
predominance (M:F ratio of 1.7:1). In contrary to acute ITP in children, adult ITP is usually 
insidious in onset, with platelet counts of > 20 x 109/L.  The incidence of chronic ITP is 5.8 to 
6.6 per 100,000 in the adult population.  
2. Definition of chronic ITP 
While ITP in children usually pursues an acute and self-limited clinical course that 
responds well to treatment, ITP in adults tends to present as a chronic relapsing 
condition. Traditionally, the terms chronic ITP, refractory ITP, and chronic persistent ITP 
are used interchangeably and are used for chronic phase of the disease. Chronic or 
refractory ITP was previously defined as immune thrombocytopenia persisting for >3 
months, failure to respond to splenectomy, and platelet count of less than 50 x 109/L. The 
definition has become more confusing since the evolution of splenectomy sparing 
modalities of treatment.  
The International Working Group (IWG) consensus panel of both adult and pediatric 
experts in ITP recently provided guidance on terminology, definitions and outcome criteria 
for this disorder (Proven et al., 2010). Primary ITP, as defined by the IWG, is platelet count 
less than 100 x 109/L in the absence of other causes or disorders that may be associated with 
thrombocytopenia. IWG used a higher platelet cutoff than the traditional criterion of 50 x 
109/L based on the observation that there might be physiological variations among different 
racial groups and that the chances of developing persistent thrombocytopenia of less than 
100 x 109/L over 10 years of follow-up seemed to be less in patients presenting with a 
platelet count between 100 and 150 x 109/L. 
The IWG also categorizes ITP as newly diagnosed (diagnosis to 3 months), persistent (3 to 12 
months from diagnosis) or chronic (lasting for more than 12 months). However, these 
definitions may not apply to patients with secondary forms of ITP and have not been 
formally validated. Specifically, “persistent ITP” includes patients not achieving 
spontaneous remission or not maintaining therapeutic response after stopping treatment 
between 3 and 12 months from initial diagnosis. The category “chronic ITP” is reserved for 
patients with ITP lasting for more than 12 months.  
The IWG standardization does not include the degree of thrombocytopenia in classifying the 
different phases of the disease. The severity of disease varies in patients. Mild, moderate, 
and severe thrombocytopenia is used commonly in clinical practice. There are no firm 
guidelines.  However, mild thrombocytopenia typically ranges from 50 to 100 x 109/L, 
moderate thrombocytopenia from 20 to 50 x 109/L, and severe thrombocytopenia under 20 x 
109/L. The severity of thrombocytopenia may or may not correlate well with the risk of 
bleeding. It is well known that the severity and symptoms of ITP in the same patient can 
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vary from time to time. Table 1 summarizes the different terminologies commonly used to 




Platelet count less than 100 x 109/L in the absence 
of other causes of thrombocytopenia 
Newly diagnosed ITP From initial diagnosis to 3 months 
Persistent ITP From 3-12 months of initial diagnosis 
Chronic ITP ITP lasting for greater than 12 months 
Mild Thrombocytopenia Platelet count between 50-100 x 109/L 
Moderate Thrombocytopenia Platelet count between 20-50 x 109/L 
Severe thrombocytopenia Platelet count below  20 x 109/L 
Table 1. Commonly used definitions in ITP 
3. Diagnosis of chronic ITP 
Fifty years since the discovery of platelet autoantibodies, there is still no definitive 
laboratory diagnostic test for ITP. Despite the tremendous advances made in the 
understanding of the pathophysiology, the diagnosis of ITP remains one of exclusion. An 
initial complete history and physical examination is essential to identify evidence of 
bleeding and exclude other etiologies of thrombocytopenia or secondary ITP.  Secondary 
causes of thrombocytopenia include autoimmune disorders as well as exposure to drugs 
(such as quinine), herbs, foods and other substances. A peripheral smear examination 
usually helps to exclude other hematological disorders, such as thrombotic 
thrombocytopenic purpura, leukemia, and pseudothrombocytopenia from platelet 
aggregation. Testing for hepatitis C and HIV infection is recommended for all patients 
presenting as ITP (Cines et al., 2005, 2009, 2010).  
Glycoprotein-specific assays to detect platelet-associated IgG (PAIgG) autoantibodies lack 
sufficient sensitivity for them to be of use as a diagnostic tool. Therapeutic response to IVIG 
is considered by many as confirmatory of ITP, in the absence of identifiable causes of 
thrombocytopenia.  As per American Society of Hematology guidelines, there is insufficient 
evidence for the utility of routine testing for anti-platelet antiphospholipid and antinuclear 
antibodies, and thrombopoietin levels. There have been recent reports achieving remission 
in chronic ITP patients with the eradication of Helicobacter pylori infection.  Even though 
there is insufficient evidence to support routine testing for Helicobacter pylori organisms, 
patients with gastrointestinal symptoms should be investigated further.  
Although 2010 ASH guidelines did not find evidence to support an age threshold for which 
bone marrow is recommended, most hematologists would favor performing bone marrow 
examination for patients over 60 years of age to rule out myelodysplasia.  This practice is 
especially useful prior to splenectomy in these older patients who do not show good 
response to treatment. The diagnosis of ITP should always be reassessed during the course 
of treatment if any atypical clinical or laboratory abnormalities develop to suggest lupus 
and other autoimmune or hematological disorder. Table 2 outlines the utility of various 
diagnostic tests for diagnosing ITP according to current guidelines. 
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Diagnostic Evaluation Recommended Optional 
Personal & Family History of 
Autoimmune Disorders 
√  
Complete Blood Count and 
Peripheral Smear Examination 
√  
ESR ANA and Anticradiolipin 
Antibodies 
 √ 
Blood Group & Direct 
Antiglobulin Test 
 √ 
HCV & HIV Serologies √  
Antiplatelet Antibodies x  
Bone Marrow Aspiration and 
Biopsy 
x Prior to splenectomy in 
patients over 60 years, with 
poor response to medical 
therapy 
Thrombopoietin Level x  
Table 2. Diagnostic tools for chronic ITP 
4. Pathogenesis 
Since the 1950s, ITP has been firmly established as an acquired autoimmune disorder 
characterized by low platelet count (Evans et al., 1951). In recent years, there have been 
significant new insights into the pathophysiologic mechanisms of ITP.  Historically, the 
thrombocytopenia associated with ITP was attributed solely to autoantibodies causing 
platelet destruction.  More recently, it has become evident that the pathophysiology in ITP 
is complex and multifaceted. In addition to a humoral-mediated mechanism, cytotoxic T-
cells and impaired platelet production by abnormal megakaryocytes have recently been 
found to be important pathogenetic factors in subsets of patients.  Our evolving 
knowledge of the pathogenesis of ITP has led to new therapeutic targets in the clinical 
management of ITP. 
4.1 Autoantibody-mediated platelet destruction 
In the mid-1900s, it was observed that when experimental subjects were infused with 
plasma from ITP patients, these subjects developed dose-dependent thrombocytopenia 
(Harrington et al., 1953).  Subsequently, it was shown that the inciting plasma factor was an 
antiplatelet antibody and that ITP was autoimmune in nature (Schulman et al., 1965). 
Platelet-associated autoantibodies are detectable in 50% to 70% of patients with ITP using 
currently available laboratory methods.  Approximately 75% of the autoantibodies detected 
are directed against the platelet surface glycoprotein (GP) complexes GPIIb-IIIa and GPIb-IX 
(Hou, et al., 1995).  Antibodies against other glycoproteins (GPIa-IIa, IV, and V) are less 
commonly found (Chang et al. 2003). 
These autoantibodies are primarily of the IgG heavy chain type, but IgM and IgA may also 
be involved (Schulman, et al., 1965).  The antibodies are secreted by autoreactive B-cells 
which are activated by autoreactive CD4+ helper T-cells.  In fact, the pathway that leads to 
platelet destruction involves a complex interplay of the humoral and cellular immune 
systems.   
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The initial trigger for the abnormal autoantibody response is unknown.  The cause of this 
loss of self-tolerance probably varies among patients.  However, the common pathway 
appears to involve CD4+ helper T-cells reacting with a specific platelet-associated antigen 
on the surface of an antigen-presenting cell (such as macrophage, dendritic cell or B-cell).  
These activated helper T cells produce cytokines that stimulate B-cells to produce specific 
antibodies.  These cytokines can also lead to expansion of CD8+ cytotoxic T-cells. 
The primary site of platelet destruction is the spleen, and to a lesser extent, the liver and 
bone marrow.  In these organs, antibody-sensitized platelets are destroyed by phagocytic 
cells. 
4.2 Role of cytotoxic T-cells 
In 30% or more of the ITP patients with no detectable anti-platelet antibody (Harrington, et 
al., 1953), alternative mechanisms of platelet destruction are likely to play a role.  Recent 
studies suggest that platelet lysis by CD8+ cytotoxic T-cells may be an important 
pathogenetic pathway in some ITP patients.  These T-cells show increased expression of 
cytotoxic genes, including tumor necrosis factor α, perforin, granzyme A and granzyme B.  
In addition to causing lysis of platelets, cytotoxic T-cells may damage megakaryocytes in the 
bone marrow (Olsson et al, 2003).  Therefore, downregulation of cytotoxic T-cell response 
serves as a potentially effective therapeutic target, especially in ITP patients who are 
refractory to conventional treatment regimens (Sabnani & Tsang, 2007). 
4.3 Impaired platelet production 
Besides accelerated platelet destruction, abnormal megakaryocytic growth and development 
are involved in the pathogenesis of ITP.  Bone marrow examination under the microscope 
characteristically reveals normal to increased numbers of megakaryocytes in ITP patients.  
There may also be a shift to younger forms of megakaryocytes.  Despite an apparently 
adequate number of megakaryocytes, platelet production is impaired.  Studies of platelet 
production have demonstrated decreased or normal turnover in greater than 70% of ITP 
patients, suggesting an impaired compensatory response of the megakaryocytes to ongoing 
platelet destruction (Chang et al., 2003; McMillan, et al., 2004).  In fact, bone marrow 
ultrastructural studies have demonstrated abnormalities in 50% to 75% of megakaryocytes 
in ITP patients.  These megakaryocytes show impaired maturation and platelet release, and 
are unable to adequately compensate for the peripheral platelet destruction (Houwerzijl, et 
al, 2004).   
Produced primarily in the liver, thrombopoietin (TPO) is the hormone responsible for 
enhancing megakaryocytic maturation and platelet production (Kuter, 2007).  When platelet 
levels are low, free TPO normally increases in the circulation, which then stimulates 
megakaryocyte proliferation.  However, serum levels of TPO fail to increase appropriately 
in response to thrombocytopenia in ITP patients (Kogusi, et al., 1996).  Since TPO binds to 
both megakaryocytes and platelets, free TPO becomes less available as TPO binds to an 
increased number of megakaryocytes in the marrow.  Furthermore, as platelets to which 
TPO binds are cleared from the circulation at an increased rate, TPO in turn becomes limited 
and platelet production is reduced (Kogusi, et al., 1996).  These observations involving 
impaired megakaryocytic growth and relative deficiency of TPO levels have opened new 
treatment possibilities that involve targeting TPO to stimulate megakaryocytic proliferation 
and platelet production in ITP. 
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5. Therapeutic challenges and options 
5.1 Clinical course of ITP 
The clinical spectrum of ITP is as heterogeneous as its pathogenesis. Spontaneous 
remissions occur very rarely. Although the majority of patients with chronic ITP require 
some type of therapeutic intervention, most have favorable long-term outcomes. However, 
mortality and morbidity are substantial in patients with severe disease that is refractory to 
treatment. Despite undergoing splenectomy after initial steroid trial, approximately one-
third of ITP patients fail to sustain platelets above 150 × 109/L, and 15% to 30% of these 
patients will require continuous therapy to sustain platelets above 30 × 109/L. Patients with 
chronic ITP and persistent platelet counts below 30 × 109/L have a 4-fold higher risk of 
mortality than that of the general population. Mortality attributable to thrombocytopenia is 
usually caused by severe bleeding and infection. Overall, approximately 10% of all patients 
with ITP are expected to develop refractory disease, posing significant challenge in clinical 
management. In general, the chances of remission lessen as the duration of chronic ITP 
increases. 
5.2 Decision to treat chronic ITP 
The decision to treat a patient is usually based upon the individual patient’s risk of bleeding. 
Treatment of patients with ITP is influenced by multiple factors, such as the age of the 
patient, severity of the illness, and the anticipated natural history. At the present time, 
treatment for ITP is considered appropriate for symptomatic patients and for those at risk of 
bleeding. Other factors influencing the decision to treat include a previous history of 
bleeding episodes, active lifestyle (such as playing contact sports), as well as other risk 
factors for bleeding such as hypertension, cerebrovascular disease, antiplatelet therapy, and 
the need for surgery or other invasive procedures. In such situations, treatment can be 
intermittent for a limited duration unless symptomatic thrombocytopenia persists.  
The main goal for treating chronic ITP should be to achieve hemostatic platelet count. 
Hemostatic platelet count can be defined as the platelet count safe enough in an individual 
patient to prevent bleeding. Except for patients with severe thrombocytopenia (<20,000 x 
109/L), platelet count is not a reliable surrogate marker for the risk of serious bleeding. 
Hemostatic platelet count varies in different patients. Most of the studies have shown that 
the risk of bleeding increases with platelet counts of less than 20 to 30 x 109/L. Generally, 
treatment for adults is recommended when platelets fall below 20 to 30 x109/L to avoid life-
threatening bleeding episodes.  
Management of patients with platelet counts between 30 to 50 x 109/L requires 
individualization and clinical judgment. Since the natural history of ITP varies in each 
individual patient, the most important factor in treating such ITP patient is to establish the 
individual record of symptomatology. While establishing the natural history of ITP, it is 
advisable to keep the platelet count above 30 x 109. Patients with platelet count greater than 
50 x 109/L should be treated in the event of active bleeding or anticipated surgical 
procedures that carry a high risk of bleeding. 
The management of chronic ITP varies from observation to aggressive treatment, including 
stem cell transplantation (Passabeg & Rabusin, 2008). The most critical player in the 
management of ITP patient is an educated patient. It is strongly suggested that patients 
understand the full spectrum of options and uncertainties surrounding treatment of this 
disorder. The availability of technology and support groups has made patients education 
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better.  Therapeutic options for chronic ITP are reflective of our understanding of the 
various pathogenic mechanisms of ITP. 
5.3 Therapeutic challenges and dilemmas 
Despite recommendations from ASH and IWG, there is no single standard treatment of 
chronic ITP. Once again, treatment should be highly individualized based on the natural 
history of ITP in the particular individual. Selection of treatment modality is based on age, 
co-morbid conditions, anticipated efficacy and adverse effects, as well as physician and 
patient preferences. Overall, the outcome of ITP has improved significantly in the last two 
decades with the advent of better mapping of the pathophysiology and the availability of 
new therapeutic agents. Since no single agent is effective in all patients, selecting a treatment 
regimen that is effective with tolerable toxicity is a challenging task.  
 
 
Fig. 1. Treatment modalities targeting various pathophysiologic mechanisms in chronic ITP 
      T-cells
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5.4 Initial treatment of chronic ITP: 
Once the diagnosis of persistent or chronic ITP is established and the need for the treatment 
is determined, underlying infection must be ruled out. Traditional modalities, such as 
steroids and immunosuppression, could be detrimental in the presence of infection. 
Intermittent courses of steroids and IVIG are used along with other immunosuppressive 
modalities. The most commonly used regimens are prednisone at a dose of 1 mg/kg per day 
orally. The popularity of pulse dosing of high-dose dexamethasone is rising (40 mg/day for 
4 days) due to the convenience of short duration of treatment (Cheng et al., 2003). The 
reported success rate with pulse dexamethasone in chronic ITP is conflicting, and long-
lasting durable responses are generally not expected. Intravenous immunoglobulins (dose 1-
2gm/kg) can also be used if there is a need to increase platelet count rapidly. Other 
alternative option is anti-D therapy. It is only recommended in Rh-positive and non-
splenectomized patients. Intermittent anti-D therapy can be used on a long-term basis but 
the potential risk of severe hemolysis should be taken into consideration.  
5.5 Second line treatment 
Until recently, splenectomy was the most common second line option for the treatment of 
refractory chronic ITP. The use of the anti-CD20 monoclonal antibody, rituximab, as a B-cell 
depletion therapy has gained tremendous popularity as a spleen saving treatment modality. 
Rituximab can be used alone or in combination with dexamethasone. However, the 
complete durable response rate is not as high as splenectomy( Schweizer et al. 2007). 
Relapsed patients can benefit from re-treatment with rituximab. Long-term 
immunosuppression and progressive multifocal encephalopathy remains potential serious 
complications with rituximab use. 
5.6 The role of splenectomy: 
Splenectomy still remains the most effective second line option and offers the highest rate of 
durable complete remissions. Splenectomy has been shown to lead to durable response in 
60% to 70% of patients (Kumar et al. 2002). However, with the introduction of a number of 
novel treatments, some clinicians recommend delaying splenectomy until later in the course 
of the illness. Despite the reduced morbidity and mortality with laparoscopic splenectomy 
in the hands of experienced surgeons, prophylactic appropriate vaccination, and use of 
antibiotics promptly in the event of febrile illness in post-splenectomy patients; still fewer 
patients are opting for splenectomy. 
5.7 Therapeutic options after splenectomy failure 
Treatment of patients with refractory ITP following splenectomy is challenging.  While 
many drugs are available, no one treatment is widely accepted (McMillan & Durette, 2004). 
Intensive treatment should be reserved for patients with persistently low platelet counts in 
the presence of bleeding. Figure 2 shows an algorithm for managing ITP patients at different 
severities of disease.  Other important considerations in the management of chronic ITP 
include the time to onset of efficacy, duration of benefit, and whether patients are able to 
maintain a response off therapy or if continued, the drug dosage necessary to maintain safe 
platelet counts.  
Several immunosuppressive agents alone or in combination have shown some efficacy, 
including azathioprine (Quiquandon et al 1990), danazol, cyclophosphamide, 
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mycophenylate mofetil (Hou et al. 2003), cyclosporine (Emilia et al. 2001), and vinca 
alkaloids. Another factor to consider when choosing an agent is patient preference for an 
oral agent administered daily, or an intravenous agent administered intermittently in an 
infusion clinic. Hematopoietic stem cell transplantation is used very rarely to treat ITP that 
has proven to be very refractory to treatment.  
 
 
Fig. 2. Algorithm For the Management of Chronic ITP: “Individualize, individualize, and 
individualize” 
Our better understanding of the immunopathogenesis has lead to the development of many 
novel therapies in the management of chronic ITP. Thrombopoietin receptor agonists 
(TRAs), which bind and activate the thrombopoietin (TPO) receptor to stimulate platelet 
production, have opened a new door in the management of chronic refractory ITP. 
Romiplastin (TPO peptide mimetic) and eltrombopag (nonpeptide TPO mimetic) are two 
recently approved agents for the treatment of refractory ITP (Burzynski, 2009). These agents 
have the advantage compared to recombinant TPO agonists of not causing the development 
of antibodies. The response rate of these agents ranges somewhere between 37% and 50%. 
To date, the clinical experience with these novel agents for a relatively benign disease is 
limited. Despite showing a favorable safety profile to date, these agents may have potential 
long-term side effects, such as thrombosis and myelofibrosis. 
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In summary, the diagnosis and management of chronic ITP require a highly individualized 
approach that is often based on the natural history of the disease in the particular patient as 
well as the experience of the physician. Published guidelines can certainly provide some 
guidance to the physicians but the decision of when and how to treat the thrombocytopenia 
will still depend upon the hematologists. Although ITP is an old disease, our recent 
understanding of the pathogenesis has caused a marked paradigm shift. For decades, 
steroids and IVIg have remained frontline treatment.  Recently, the developments of newer 
therapies, such as rituximab and thrombopoietic agonists, have had a major impact on the 
management of ITP. A combination of different agents may be a useful approach in the 
future but a single uniform set of guidelines is difficult to establish. To date, optimizing the 
curative effects of the different therapies available remains a challenge. 
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